CheckMate142: Checkpoint combination therapy in first-line colorectal cancer
Dr Lenz speaks with ecancer at ESMO 2018 in Munich about the CheckMate 142 trial of nivolumab with ipilimumab as first-line therapy in DNA mismatch repair deficient (dMMR) and microsatellite instability high (MSI-high) metastatic colorectal cancer (mCRC). He outlines previous research into differing doses of the combination, and reports the improved disease control rate, response rate and tolerability of this trials 6 week schedule. The use of checkpoint combination therapy in early colon cancer as neo-adjuvant therapy is also discussed by Dr Myriam Chalabi.
